Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combinat...

Full description

Saved in:
Bibliographic Details
Main Authors GOFF DANE A, HARRISON STEPHEN D, BROWN SEAN P, RING DAVID B, SEELY LYNN, JOHNSON KIRK W, RENHOWE PAUL A, NUSS JOHN M, ZHOU XIAOHUI A, WAGMAN ALLAN S, BOYCE RUSTUM S, RAMURTHY SAVITHRI, SUBRAMANIAN SHARADHA, PFISTER KEITH B
Format Patent
LanguageEnglish
Published 03.12.2002
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
Bibliography:Application Number: US19990336098